Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study.

Jarcho JM, Chang L, Berman M, Suyenobu B, Naliboff BD, Lieberman MD, Ameen VZ, Mandelkern MA, Mayer EA.

Aliment Pharmacol Ther. 2008 Aug 1;28(3):344-52.

2.

The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.

Mayer EA, Berman S, Derbyshire SW, Suyenobu B, Chang L, Fitzgerald L, Mandelkern M, Hamm L, Vogt B, Naliboff BD.

Aliment Pharmacol Ther. 2002 Jul;16(7):1357-66.

3.
4.

The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.

Nakai A, Diksic M, Kumakura Y, D'Souza D, Kersey K.

Neurogastroenterol Motil. 2005 Apr;17(2):212-21.

PMID:
15787942
5.

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.

Berman SM, Chang L, Suyenobu B, Derbyshire SW, Stains J, Fitzgerald L, Mandelkern M, Hamm L, Vogt B, Naliboff BD, Mayer EA.

Gastroenterology. 2002 Oct;123(4):969-77.

PMID:
12360456
6.

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG.

Clin Gastroenterol Hepatol. 2004 Aug;2(8):675-82.

PMID:
15290660
7.

Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.

Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C.

Aliment Pharmacol Ther. 2000 Jul;14(7):869-78.

8.

Alosetron and irritable bowel syndrome.

Mayer EA, Bradesi S.

Expert Opin Pharmacother. 2003 Nov;4(11):2089-98. Review.

PMID:
14596662
9.

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.

Arch Intern Med. 2001 Jul 23;161(14):1733-40.

PMID:
11485506
10.

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.

Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG.

Aliment Pharmacol Ther. 1999 Nov;13(11):1419-27.

11.

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.

Am J Gastroenterol. 2007 Aug;102(8):1709-19. Epub 2007 May 17.

PMID:
17509028
13.
14.

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J.

Aliment Pharmacol Ther. 1998 Sep;12(9):849-55.

15.

The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.

Lewis JH.

Drug Saf. 2011 Jul 1;34(7):545-65. doi: 10.2165/11590690-000000000-00000. Review.

PMID:
21663331
16.

Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?

Cash BD, Lacy BE, Rao T, Earnest DL.

Expert Opin Pharmacother. 2016;17(3):311-22. doi: 10.1517/14656566.2016.1118052. Epub 2015 Dec 8. Review.

PMID:
26559529
17.

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E; Lotronex Investigator Team.

Am J Gastroenterol. 2001 Sep;96(9):2662-70.

PMID:
11569692
18.

[Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].

Komoto S, Miura S.

Nihon Rinsho. 2006 Aug;64(8):1487-90. Review. Japanese.

PMID:
16898618
19.

Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.

Lembo A, Weber HC, Farraye FA.

Drugs. 2003;63(18):1895-905. Review.

PMID:
12930162
20.

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M.

Clin Gastroenterol Hepatol. 2008 May;6(5):545-55. doi: 10.1016/j.cgh.2007.12.015. Epub 2008 Jan 31. Review.

Supplemental Content

Support Center